To explore the effects of therapeutic targeting of Ikaros and Aiolos on B cell activation in the context of SLE, we isolated B cells from blood samples from patients with SLE and stimulated them in vitro with TLR7 agonist resiquimod in combination with IFNα for 5 days, without or with the cereblon modulator iberdomide (figure 1A). Here, IKZF3 is linked to systemic lupus erythematosus.